Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo Controlled, Randomized, Cross-over, Phase IIa Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia in Healthy Subjects

NCT00962481 is registered in ClinicalTrials.gov with Revotar Biopharmaceuticals AG as lead sponsor.

NCT NCT00962481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00962481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo Controlled, Randomized, Cross-over, Phase IIa Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia in Healthy Subjects
Lead sponsor
Revotar Biopharmaceuticals AG
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)